The Quantellect read.As of Nov 19, 2026, 10 active firms cover Compass Therapeutics Inc: 9 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $1.00 to $30.00 (about 30.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $9.00 sits 1393% above the current $0.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.13 next quarter toward $-0.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy990%
Neutral110%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.00
+1393.3% upside
Average target across 8 active firms as of Nov 19, 2026 vs $0.60 current
Highest Target$30.00
Average Target$9.00
Lowest Target$1.00
Detailed analyst forecasts for CMPX
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 9 of 10 active firms rate CMPX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CMPX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.16 – $-0.11 · 6 analysts · +32% YoY
Next period, 6 analysts expect Compass Therapeutics Inc. to earn $-0.13 a share (range $-0.16 – $-0.11), versus $-0.10 a year earlier. Full-year consensus is $-0.51, growing to $-0.59 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $2.7M next year.
Top analysts covering Compass Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CMPX.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$4.00+563.7% to target
Overall win rate
53%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #162
Buy
$7.00+1061.4% to target
Overall win rate
53%
+ Follow
#3
Li Watsek
Cantor Fitzgerald · Rank #357
Buy
No targeton CMPX
Overall win rate
38%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$12.00+1891.0% to target
Overall win rate
34%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #474
Buy
No targeton CMPX
Overall win rate
29%
+ Follow
CMPX stock forecast FAQ
What is CMPX's average 12-month price target?+
The 8 active firms with a live target average $9.00 for Compass Therapeutics Inc. over the next 12 months, ranging from a $30.00 high to a $1.00 low, as of Nov 19, 2026.
Is CMPX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CMPX?+
The Street-high target is $30.00 (D. Boral Capital), and the Street-low is $1.00 (Wedbush). The average of all 8 active-firm targets is $9.00.
How many active Wall Street firms cover CMPX?+
10 active firms have a recognized rating on Compass Therapeutics Inc. as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CMPX?+
Among analysts who currently cover CMPX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $4.00 target.
What is Compass Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.16 – $-0.11) across 6 analysts. Full-year EPS is projected at $-0.51, rising to $-0.59 the following year.
How much revenue is Compass Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $2.7M next year.
Have analysts been upgrading or downgrading CMPX lately?+
As of Nov 19, 2026, 9 of 10 active firms rate CMPX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CMPX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.